RVTY — Revvity, Inc.

RVTY Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $772 million, representing 4% organic growth.
• Full Year Revenue: $2.86 billion, with 3% organic growth.
• Adjusted EPS: $1.70 for Q4, exceeding guidance; $5.06 for the full year, up 3% year-over-year.
• Adjusted Operating Margins: 29.7% in Q4; 27.1% for the full year, down 120 basis points year-over-year.
• Free Cash Flow: $162 million in Q4; $515 million for the full year, equating to 87% conversion of adjusted net income.
• Share Repurchase: Over $800 million in 2025, reducing share count by 8.5 million shares.

2. Strategic Updates and Business Highlights

• Diagnostics Segment: Strong performance with 7% organic growth in Q4, driven by reproductive health and immunodiagnostics.
• Life Sciences Segment: Flat organic growth year-over-year, with low single-digit growth from pharma customers and a decline from academic/government sectors.
• Acquisition: Closed on ACD Labs acquisition, expected to contribute over $20 million in revenue and add approximately 75 basis points to overall growth in 2026.
• AI Initiative: Launch of the AI models as a service platform, Signals Synthetica, aimed at enhancing drug development efficiency.

3. Forward Guidance and Outlook

• 2026 Organic Growth: Expected to be in the range of 2% to 3%, with potential upside if end market conditions improve.
• Total Revenue Guidance: Projected between $2.96 billion and $2.99 billion, including FX tailwinds and ACD acquisition contributions.
• Adjusted EPS Guidance: Expected to be between $5.35 and $5.45, indicating high single-digit growth.
• Operating Margins: Anticipated to be around 28% for 2026, with improvements expected in the second half of the year due to cost efficiency initiatives.

4. Bad News, Challenges, or Points of Concern

• Market Headwinds: Continued uncertainty in NIH funding, tariffs, and the impact of the US government shutdown affecting diagnostics.
• China Diagnostics: Anticipated decline in immunodiagnostics revenue due to DRG-related volume pressures, with no expected return to growth in the second half of 2026.
• Life Sciences Segment: Cautious outlook due to flat growth and uncertainty in academic and government spending.
• Margins: Expected pressure in Q1 margins due to additional costs from an extra operating week and ongoing cost-saving initiatives.

5. Notable Q&A Insights

• Organic Growth Guidance: Analysts questioned the conservativeness of the 2% to 3% guidance, with management acknowledging potential upside from improving biotech funding and market conditions.
• Life Sciences vs. Diagnostics: Management indicated that both segments are expected to contribute similarly to the organic growth target, with diagnostics potentially providing upside.
• Software Launches: New product launches in the software segment are anticipated to enhance growth, but management is cautious about embedding significant contributions in the 2026 guidance.
• Competitive Dynamics: Management noted that they have not seen margin dilution in the reagents business despite competitive pressures, and they continue to gain market share.

Overall, Revvity demonstrated resilience in a challenging environment, achieving strong financial results and strategic advancements while maintaining a cautious outlook for 2026 amidst ongoing market uncertainties.